Keywords
How to Cite
Abstract views: 536 PDF Downloads: 404
Abstract
Intestinal microbiota is a factor that determines human health, maintains body homeostasis, and influences the development of pancreatic diseases (acute pancreatitis, chronic pancreatitis (CP), and cancer). Butyrate, acetate, propionate, and key short-chain fatty acids, which are synthesized by probiotic bacteria, have a significant effect on the functional pancreatic activity: anti-inflammatory effect, modulation of pancreatic β-cell function, regulation of pancreatic cell mass, and strengthening of the intestinal barrier function.
It has been proven that the course of CP is associated with intestinal dysbiosis, bacterial overgrowth syndrome, a decrease in the levels of Firmicutes and Actinobacteria, and an increase in the levels of Proteobacteria phylum, Eubacterium rectale, Coprococcus, Sutterella, and Eubacterium ruminantium. Their predominance is related to exocrine pancreatic insufficiency, while Pseudomonas, Fusobacterium, and Ruminococcus gnavus are more common in CP patients without exocrine pancreatic insufficiency. Activation of pancreatic fibrogenesis is associated with an increase in Streptomyces, Turicibacter, Methylobacterium, Enterococcus, and Candidatus Paenicardiniummore.
The mechanism of action of probiotics in pancreatic diseases is associated with improved functioning of the intestinal barrier, decreased BOS and the inflammatory process, and inhibition of the signaling pathway of oncogenesis. The microbiome-associated approach to treating CP is based on the additional administration of probiotics. The multicomponent probiotic Laktiale Multi can be the drug of choice.
References
Abdul Rahman R., Lamarca A., Hubner R., Valle J. W., McNamara M. G. The microbiome as a potential target for therapeutic manipulation in pancreatic cancer. Cancers (Basel). 2021. Vol. 13, No 15. P. 3779.
Binda C., Gibiino G., Sbrancia M., Coluccio C., Cazzato M., Carloni L., Cucchetti A., Ercolani G., Sambri V., Fabbri C. Microbiota in the natural history of pancreatic cancer: from predisposition to therapy. Cancers (Basel). 2022. Vol. 15, No 1. P. 1.
Brubaker L., Luu S., Hoffman K., Wood A., Cagigas M. N., Yao Q., Petrosino J., Fisher W., Van Buren G. Microbiome changes associated with acute and chronic pancreatitis: a systematic review. Pancreatology. 2021. Vol. 21, No 1. P. 1–14.
Chonchubhair H. M., Bashir Y., Dobson M., Ryan B. M., Duggan S. N., Conlon K. C. The prevalence of small intestinal bacterial overgrowth in non-surgical patients with chronic pancreatitis and pancreatic exocrine insufficiency (PEI). Pancreatology. 2018. Vol. 18, No 4. P. 379–385.
El Kurdi B., Babar S., El Iskandarani M., Bataineh A., Lerch M. M., Young M., Singh V. P. Factors that affect prevalence of small intestinal bacterial overgrowth in chronic pancreatitis: a systematic review, meta-analysis, and meta-regression. Clin. Transl. Gastroenterol. 2019. Vol. 10, No 9. P. e00072.
Fan X., Alekseyenko A. V., Wu J., Peters B. A., Jacobs E. J., Gapstur S. M., Purdue M. P., Abnet C. C., Stolzenberg-Solomon R., Miller G., Ravel J. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut. 2018. Vol. 67, No 1. P. 120–127.
Fernández-Millán E., Guillén C. Multi-organ crosstalk with endocrine pancreas: a focus on how gut microbiota shapes pancreatic beta-cells. Biomolecules. 2022. Vol. 12, No 1. P. 104.
Frost F., Weiss F. U., Lerch M. M. Rolle des Mikrobioms bei Erkrankungen des Pankreas [The role of the microbiome in diseases of the pancreas]. Internist (Berl). 2022. Vol. 63, No 4. P. 372–378. German.
Frost F., Weiss F. U., Sendler M., Kacprowski T., Rühlemann M., Bang C., Franke A., Völker U., Völzke H., Lamprecht G., Mayerle J. The gut microbiome in patients with chronic pancreatitis is characterized by significant dysbiosis and overgrowth by opportunistic pathogens. Clin. Transl. Gastroenterol. 2020. Vol. 11, No 9. P. e00232.
Gu Y., Chen H., Li X., Li D., Sun Y., Yang L., Ma Y., Chan E. C. Lactobacillus paracasei IMC 502 ameliorates type 2 diabetes by mediating gut microbiota-SCFA-hormone/inflammation pathway in mice. J. Sci. Food Agric. 2023. Vol. 103, No 6. P. 2949–2959.
Guarner F., Sanders M. E., Szajewska H., Cohen H., Eliakim R., Herrera C., Karakan T., Merenstein D., Piscoya A., Ramakrishna B., Salminen S. World Gastroenterology Organization. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics. February 2023. URL: https://www.worldgastroenterology.org/guidelines/probiotics-and-prebiotics/probiotics-and-prebiotics-english (Last accessed: 10.04.2023).
Hasain Z., Raja Ali R. A., Ahmad H., Abdul Rauf U. F., Oon S. F., Mokhtar N. M. The roles of probiotics in the gut microbiota composition and metabolic outcomes in asymptomatic post-gestational diabetes women: a randomized controlled trial. Nutrients. 2022. Vol. 14, No 18. P. 3878.
Jandhyala S. M., Madhulika A., Deepika G., Rao G. V., Reddy D. N., Subramanyam C., Sasikala M., Talukdar R. Altered intestinal microbiota in patients with chronic pancreatitis: Implications in diabetes and metabolic abnormalities. Sci. Rep. 2017. Vol. 7. P. 1–10.
Jo S., Fang S. Therapeutic strategies for diabetes: immune modulation in pancreatic β cells. Front. Endocrinol. (Lausanne). 2021. Vol. 12. P. 716692.
Kim T. K., Lee J.-C., Im S.-H., Lee M.-S. Amelioration of autoimmune diabetes of NOD mice by immunomodulating probiotics. Front. Immunol. 2020. Vol. 11. P. 1832.
Lee A. A., Baker J. R., Wamsteker E., Saad R., DiMagno M. J. Small intestinal bacterial overgrowth is common in chronic pancreatitis and associates with diabetes, chronic pancreatitis severity, low zinc levels, and opiate use. Am. J. Gastroenterol. 2019. Vol. 114, No 7. P. 1163–1171.
Liu L., Zhang T., Sui Y., Li G., Liu L., Lu T., Tan H., Sun B., Li X., Li L. Gut microbiota affects pancreatic fibrotic progression through immune modulation in chronic pancreatitis. Microb. Pathog. 2023. Vol. 177. P. 106035.
Maekawa T., Fukaya R., Takamatsu S., Itoyama S., Fukuoka T., Yamada M., Hata T., Nagaoka S., Kawamoto K., Eguchi H., Murata K. Possible involvement of Enterococcus infection in the pathogenesis of chronic pancreatitis and cancer. Biochem. Biophys. Res. Commun. 2018. Vol. 506. P. 962–969.
McEachron K. R., Nalluri H., Beilman G., Kirchner V. A., Pruett T. L., Freeman M. L., Trikudanathan G., Staley C., Bellin M. D. Decreased intestinal microbiota diversity is associated with increased gastrointestinal symptoms in patients with chronic pancreatitis. Pancreas. 2022. Vol. 51, No 6. P. 649–656.
Memba R., Duggan S. N., Chonchubhair H. M., Griffin O. M., Bashir Y., O’Connor D. B., Murphy A., McMahon J., Volcov Y., Ryan B. M., Conlon K. C. The potential role of gut microbiota in pancreatic disease: a systematic review. Pancreatology. 2017. Vol. 17, No 6. P. 867–874.
Mu Q., Tavella V. J., Luo X. M. Role of Lactobacillus reuteri in human health and diseases. Front. Microbiol. 2018. Vol. 9. P. 757.
Nishiyama H., Nagai T., Kudo M., Okazaki Y., Azuma Y., Watanabe T., Goto S., Ogata H., Sakurai T. Supplementation of pancreatic digestive enzymes alters the composition of intestinal microbiota in mice. Biochem. Biophys. Res. Commun. 2018. Vol. 495. P. 273–279.
Pagliari D., Saviano A., Newton E. E., Serricchio M. L., Dal Lago A. A., Gasbarrini A., Cianci R. Gut microbiota-immune system crosstalk and pancreatic disorders. Mediators Inflamm. 2018. Vol. 2018. P. 7946431.
Pan L. L., Li B. B., Pan X. H., Sun J. Gut microbiota in pancreatic diseases: possible new therapeutic strategies. Acta Pharmacol. Sin. 2021. Vol. 42, No 7. P. 1027–1039.
Peng T. R., Wu T. W., Chao Y. C. Effect of probiotics on the glucose levels of pregnant women: a meta-analysis of randomized controlled trials. Medicina (Kaunas). 2018. Vol. 54, No 5. P. 77.
Ritz S., Hahn D., Wami H. T., Tegelkamp K., Dobrindt U., Schnekenburger J. Gut microbiome as a response marker for pancreatic enzyme replacement therapy in a porcine model of exocrine pancreas insufficiency. Microb. Cell Fact. 2020. Vol. 19, No 1. P. 221.
Schepis T., De Lucia S. S., Nista E., Manilla V., Pignataro G., Ojetti V., Piccioni A., Gasbarrini A., Franceschi F., Candelli M. Microbiota in pancreatic diseases: a review of the literature. J. Clin. Med. 2021. Vol. 10, No 24. P. 5920.
Solito A., Bozzi Cionci N., Calgaro M., Caputo M., Vannini L., Hasballa I., Archero F., Giglione E., Ricotti R., Walker G. E., Petri A. Supplementation with Bifidobacterium breve BR03 and B632 strains improved insulin sensitivity in children and adolescents with obesity in a cross-over, randomized double-blind placebo-controlled trial. Clin. Nutr. 2021. Vol. 40, No 7. P. 4585–4594.
Tan C., Ling Z., Huang Y., Cao Y., Liu Q., Cai T., Yuan H., Liu C., Li Y., Xu K. Dysbiosis of intestinal microbiota associated with inflammation involved in the progression of acute pancreatitis. Pancreas. 2015. Vol. 44, No 6. P. 868–875.
Tang J., Xu L., Zeng Y., Gong F. Effect of gut microbiota on LPS-induced acute lung injury by regulating the TLR4/NF-kB signaling pathway. Int. Immunopharmacol. 2021. Vol. 91. P. 107272.
Temel HY, Kaymak Ö, Kaplan S., Bahcivanci B., Gkoutos G. V., Acharjee A. Role of microbiota and microbiota-derived short-chain fatty acids in PDAC. Cancer Med. 2023. Vol. 12, No 5. P. 5661–5675.
Tian X., Pi Y. P., Liu X., Chen H., Chen W. Q. Supplemented use of pre-, pro-, and synbiotics in severe acute pancreatitis: an updated systematic review and meta-analysis of 13 randomized controlled trials. Front. Pharmacol. 2018. Vol. 9. P. 690.
Wang Y., Dilidaxi D., Wu Y., Sailike J., Sun X., Nabi X. H. composite probiotics alleviate type 2 diabetes by regulating intestinal microbiota and inducing GLP-1 secretion in Db/Db mice. Biomedicine Pharmacotherapy. 2020. Vol. 125. P. 109914.
Wu C., Li M., Chen W. Characteristics of gut microbiota in cerulein-induced chronic pancreatitis. Diabetes Metab. Syndr. Obes. 2021. Vol. 14. P. 285–294.
Yang Q., Zhang J., Zhu Y. Potential roles of the gut microbiota in pancreatic carcinogenesis and therapeutics. Front. Cell Infect. Microbiol. 2022. Vol. 12. P. 391.
Ye S, Si C, Deng J., Chen X., Kong L., Zhou X., Wang W. Understanding the effects of metabolites on the gut microbiome and severe acute pancreatitis. Biomed. Res. Int. 2021. Vol. 2021. P. 1–10.
Yu C., Zhang Y., Yang Q., Lee P., Windsor J. A., Wu D. An updated systematic review with meta-analysis: efficacy of prebiotic, probiotic, and synbiotic treatment of patients with severe acute pancreatitis. Pancreas. 2021. Vol. 50, No 2. P. 160–166.
Zhang T., Gao G., Sakandar H. A., Kwok L. Y., Sun Z. Gut dysbiosis in pancreatic diseases: a causative factor and a novel therapeutic target. Front. Nutr. 2022. Vol. 9. P. 147.
Zhang X. M., Zhang Z. Y., Zhang C. H., Jing W. U., Wang Y. X., Zhang G. X. Intestinal microbial community differs between acute pancreatitis patients and healthy volunteers. Biomed. Environment. Sci. 2018. Vol. 31, No 1. P. 81–86.
Zhou C. H., Meng Y. T., Xu J. J., Fang X., Zhao J. L., Zhou W., Zhao J., Han J. C., Zhang L., Wang K. X., Hu L. H. Altered diversity and composition of gut microbiota in Chinese patients with chronic pancreatitis. Pancreatology. 2020. Vol. 20. P. 16–24.
Zhu Y., He C., Li X., Cai Y., Hu J., Liao Y., Zhao J., Xia L., He W., Liu L., Luo C. Gut microbiota dysbiosis worsens the severity of acute pancreatitis in patients and mice. J. Gastroenterol. 2019. Vol. 54, No 4. P. 347–358.
Zhu Y., Mei Q., Fu Y., Zeng Y. Alteration of gut microbiota in acute pancreatitis and associated therapeutic strategies. Biomed. Pharmacother. 2021. Vol. 141. P. 111850.